Galmed Pharmaceuticals Ltd. (GLMD) Form 424B3 — Jun 22, 2026
Galmed Pharmaceuticals has consummated its acquisition of Colospan Ltd., an Israeli company, pursuant to an amended share purchase agreement. The company modified the deal terms to replace a $2.0 million equity issuance with an additional $800,000 in cash, resulting in a total closing cash payment of $3.3 million. The transaction includes a performance-based earnout of up to $2.0 million based on cumulative net sales revenues starting July 1, 2027. Payments are structured with tiers of 7% on sales between $5 million and $12 million, and 9% on sales above $12 million, with the total earnout capped at $2.0 million.
Key figures
- Deal Value Usd
- 3,300,000
- Earnout Cap
- 2,000,000
- Sales Threshold1
- 5,000,000
- Sales Threshold2
- 12,000,000
- Earnout Rate Tier1
- 7%
- Earnout Rate Tier2
- 9%
- Financing Trigger
- 17,500,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.